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Abstract: Recently, microRNAs (miRNAs) in circulating extracellular vesicles (EVs), have emerged
as a source of potential biomarkers for various pathophysiological conditions, including metabolic
disorders such as diabetes. Type 2 diabetes mellitus (T2DM), is the most prevalent form of diabetes in
the USA, with 30 million diagnosed patients. Identifying miRNA biomarkers that can be used to
assess response to glucose lowering treatments would be useful. Using patient plasma samples from a
subset of the Danish Metagenomics of the Human Intestinal Tract (MetaHIT) cohort, we characterized
miRNAs from whole plasma, plasma-derived EVs, and EV-depleted plasma by small RNA-sequencing
to identify T2DM associated miRNAs. We identified several miRNAs that exhibited concentration
changes between controls and non-metformin treated T2DM patients and we validated a subset of
these by quantitative reverse transcription-polymerase chain reaction (qRT-PCR). The results showed
that the concentrations of many T2DM-affected miRNAs in EV (but not in whole or EV-depleted
plasma) decreased to levels close to those of healthy controls following metformin treatment. Among
other potential uses of these differentially expressed miRNAs, some might be useful in assessing the
response to metformin in T2DM patients.
Keywords: microRNAs; extracellular vesicles; type 2 diabetes; metformin

1. Introduction
Diabetes is a major health epidemic accounting for a significant proportion of health-care-related
expenditures in many countries [1]. In the United States alone, there are about 30 million patients
living with diabetes, the majority with type 2 diabetes mellitus (T2DM) [2]. Elevated blood glucose is
the hallmark of T2DM, which eventually leads to micro- and macro-vascular complications of major
organs, among other effects. Onset of T2DM is usually preceded by a prediabetic phase, where blood
glucose levels are elevated but below the level for T2DM. In many cases prediabetes results from
development of insulin resistance (IR) of glucose metabolizing tissues which will eventually lead to
pancreatic β-cell dysfunction. Managing the blood glucose level through exercise, dietary change,
and drug treatment are the principal approaches to T2DM management. A drug to treat T2DM is
metformin, which primarily reduces hepatic gluconeogenesis thereby lowering tissue and circulating
levels of glucose [3].
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In recent years, cell-free microRNAs (miRNAs) present in various body fluids, including those
packaged in extracellular vesicles (EVs), have emerged as potential biomarkers for various diseases
and health conditions, including T2DM [3]. There have been several studies examining the changes
of circulating miRNAs associated with T2DM. One of the earliest studies identified several T2DM
affected circulating miRNAs, and found the plasma miR-126-5p level is changed in both T2DM
patients and mouse models [4]. Other studies have also observed the association of miR-126-5p level
in plasma with insulin treatment [5–7]. Additional T2DM associated circulating miRNAs, such as
miR-30d-5p [6–8], miR-122-5p [9–11], miR-146a-5p [8,12], miR-192-5p [13,14], and miR-375-5p [7,8] have
also been reported. Several of these miRNAs, such as miR-30d-5p [9], miR-122-5p [9], miR-126-5p [5],
and miR-192-5p [15] have also been associated with prediabetes. While these circulating miRNAs
show promise for identifying individuals with T2DM, the results of our meta-analysis showed many
inconsistent findings among studies, which may have been caused by differences in sample preparation
methods or miRNA measurement platforms [16]. All miRNA measurement platforms have advantages
and disadvantages. For example, next generation sequencing (NGS) based small-RNA sequencing
(sRNAseq) provides higher dynamic range and allows for the analysis of all potential miRNAs, and
even identification of novel miRNAs, when compared to quantitative reverse transcription-polymerase
chain reaction (qRT-PCR), or microarray making it a better method for discovery-based studies. On the
other hand, sRNAseq protocols, particularly the commercial library construction kits, are prone to
severe sequence-specific biases. To address this, a modified small RNA sequencing library construction
method, as well as a comprehensive data analysis pipeline, that allows for significant improvement of
miRNA analysis from biological samples were developed [17,18]. This improved approach has been
used in several diabetes related studies, including the identification of circulating miRNAs associated
with the progression of T2DM from prediabetic individuals [19,20].
Many circulating miRNA studies do not consider EVs in circulation as a separate sample type
rather using whole biofluids, such as plasma and serum. Those few EV based studies often use
isolation methods such as ultracentrifugation or precipitation, which may alter their properties
and co-purify RNAs associated with RNA-binding proteins or lipoproteins [21,22]. There are some
technical advancements to improve the reproducibility of circulating miRNA studies in recent years.
These including a size exclusion chromatography (SEC) based EV purification, an improved small
RNA library construction method [18], and better tools to align short RNA sequence reads [17]. In the
current study, we analyzed the small RNA spectra from whole plasma, plasma EVs and EV-depleted
plasma obtained from T2DM patients (with or without metformin treatment) and from healthy control
individuals who participated in the Danish part of the Metagenomics of the Human Intestinal Tract
(MetaHIT) study [23].
Several circulating miRNAs including some EV-encapsulated miRNAs that are associated with
T2DM or affected by metformin treatment were identified. These miRNAs may serve as possible
biomarkers, assessing metformin treatment response in patients with T2DM.
2. Materials and Methods
2.1. Sample and Study Collection
Fasting plasma samples were obtained from a subset of the Danish MetaHIT cohort [23]. In the
present study we included 80 individuals: 39 controls, 10 T2DM (non-metformin treated), and 31 T2DM
(treated with metformin). Samples were matched for age, and body mass index (BMI) (Supplemental
Table S1). Anthropometrics and biochemical measurements were obtained as previously described [24].
Plasma glucose was analyzed by a glucose oxidase method (Granutest, Merck, Darmstadt, Germany).
HbA1c was measured on TOSOH G7 by ion-exchange high performance liquid chromatography. Serum
insulin (excluding des-31,32-proinsulin and intact proinsulin) was measured using the AutoDELFIA
insulin kit (Perkin-Elmer, Wallac, Turku, Finland). HOMA-IR was calculated as: (fasting plasma
glucose (mmol/L) × fasting serum insulin (mU/L))/22.514. BMI was calculated as weight (kg) divided
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by height (m2 ) and obesity defined as BMI > 30 kg/m2 . Plasma samples were collected after an
overnight fast into EDTA-treated tubes and spun at 1000× g at 4 ◦ C for 10 min to remove blood cells,
and then 2000× g at 4 ◦ C for 15 min to remove platelets and stored at −80 ◦ C. Before RNA isolation, the
plasma samples were spun at 10,000× g at 4 ◦ C for 10 min to remove any remaining cellular debris and
platelets. Prior to EV and RNA isolation, the plasma samples were spun at 10,000× g at 4 ◦ C for 10 min
to remove platelets and cellular debris.
2.2. Isolation of EV and EV-Depleted Fractions
EVs were isolated from 200 µL of plasma using size-exclusion chromatography (SEC) (qEV column,
Izon Science, Cambridge, MA, USA) with de-gassed PBS as previously described [25]. Briefly, eluate
fractions (∼500 µL each fraction) containing EVs (fractions 7–10) were collected and the subsequent
fractions (11–35) were also collected as EV-depleted fractions. To confirm the purification of EVs
from samples, the SEC-purified EVs were quantified using the qNano particle counter (Izon Science,
Cambridge, MA, USA) using a NP150 pore, and visualized with transmission electron microscopy as
previously described [21].
2.3. RNA Isolation and Small RNA Sequencing Library Construction
Circulating RNA was isolated from whole plasma, EVs, and EV-depleted fractions using the
miRNeasy kit according to the manufacturer’s instructions. The RNA was eluted in 14 µL nuclease-free
H2 O, and the quantity and quality were assessed using a Bioanalyzer pico chip (Agilent Technologies,
Santa Clara, CA, USA). To analyze circulating miRNA, we used a modified small-RNA library
construction protocol to reduce small RNA library construction associated bias [18]. Individual library
concentrations were assessed by NEBNext Library Quant Kit for Illumina (New England Biolabs,
Ipswich MA), pooled (2 nM final concentration) and then run on a NextSeq500 sequencer (Illumina,
San Diego, CA, USA).
2.4. Data Analysis
Sequence files (FASTQ format) were processed with an in-house small RNA analysis
pipeline—sRNAnalyzer [17]. Briefly, the adapters were trimmed from the sequence reads, low
complexity, low quality, and short reads (less than 15 nucleotides) were removed. The processed reads
(reads that passed filtering) were then mapped against miRBase (www.mirbase.org) v21. The mapping
was performed with single assignment and zero mis-matches allowed. The miRNA mapping results
were normalized using read count per million of processed read and then log2 transformed. Based on
the results, several invariant miRNAs (miRNAs that had a low sample to sample coefficient of
variance across all samples, including plasma, EVs, and EV-depleted plasma) were identified, including
miR-451a-5p and miR-486-5p. To be considered for analysis, a given miRNA had to have greater
than 10 reads in at least 50% of samples, across all samples, including plasma, EVs, and EV-depleted
plasma. To be considered to have a significant concentration change, a miRNA required a fold change
greater than 1.5 (or a log2 fold change > ±0.60) with a p-value < 0.05 (calculated using the Wilcoxon
rank sum test and corrected for multiple hypothesis testing using Benjamini-Hochberg). The miRTar
database (mirtar.mbc.nctu.edu.tw/ ) was used to identify miRNA-mRNA interaction targets to determine
biological processes that may be regulated by specific miRNA. In this approach, we required that each
miRNA target must be validated by at least two different experimental methods. Gene enrichment
analysis was performed with DAVID (Database for Annotation, Visualization and Integrated Discovery,
https://david.ncifcrf.gov/), using default settings. Enrichment was based on the Benjamini-Hochberg
corrected p-values for KEGG terms.
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2.5. qRT-PCR
Quantitative Reverse Transcription Polymerase Chain Reaction (qRT-PCR) validation of miRNAs
was performed using TaqMan Advanced miRNA assays (Thermo Fisher, Waltham, MA, USA).
MiR-451a-5p and miR-486-5p were used as normalizers, since they were identified as invariant
miRNAs in the sample set (low coefficient of variance across samples) based on the miRNA mapping
results. Relative miRNA values are presented by ∆∆Ct values (Ct reference − Ct target ) [26].
2.6. Ethics
The study was approved by the Ethical Committees of the Capital Region of Denmark
(HC-2008-017 and H-15000306) and was in accordance with the principles of the Declaration of
Helsinki. All individuals gave written informed consent before participating in the study.
3. Results
3.1. Isolation of EVs from Fasting Plasma Samples of Healthy Controls and T2DM
From the 80 individuals in the discovery set, 39 were healthy controls, 10 were non-metformin
treated T2DM, and 31 were metformin-treated T2DM patients (Supplemental Table S1). The samples
were matched with respect to gender, age and BMI, and showed no significant differences between the
groups (Supplemental Table S1). To explore the possible changes in circulating miRNA profiles among
the groups, we used next generation sequencing (NGS) platform to characterize the miRNA spectra
in whole plasma, EVs, and EV-depleted plasma for each patient. EVs isolated from plasma had an
average size of 122 nm, with an estimated average concentration of 4.24 × 108 EVs/mL (Figure 1A).
Electron microscopy images of EVs from these samples showed the presence of vesicles of ~100 nm in
diameter with typical morphology (Figure 1B,C). The EVs, along with whole plasma and EV-depleted
plasma, were then used to isolate RNA for small RNA analysis (Figure 1D–L).
3.2. MiRNA Levels from Small RNA Sequencing
About 10 million reads on average across all samples were obtained, among them approximately
7 million reads passed the pre-processing step (removal of adapter sequences and short or low
complexity reads) (Table 1). In plasma, about 1.1 million processed reads mapped to various human
miRNAs, while on average 293,000 and 634,000 reads mapped to various miRNAs in EV and EV-depleted
samples, respectively (Table 1). In whole plasma, EVs, and EV-depleted plasma on average 693, 423,
and 617 different miRNAs were observed (with at least one mapped read) in each sample, respectively.
Among these observed miRNAs in whole plasma, EVs, and EV-depleted plasma, 446, 242, and 352
miRNAs had 10 or more mapped reads, respectively (Table 1).
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Table 1. Overview of sequencing results.
Fraction

Whole Plasma

Sample

Control

T2DM
(Non-Metformin
Treated)

Raw reads
Processed reads
Reads mapped to miRNA
Observed (>1 mapped)
Detected miRNAs (>10 reads)

9,883,520
7,103,119
1,156,073
685
423

11,530,667
7,633,060
1,215,783
706
472

T2DM
(Metformin
Treated)
10,712,888
7,373,665
1,166,777
688
445

EV
Average

Control

T2DM
(Non-Metformin
Treated)

10,709,025
7,369,948
1,179,544
693
446

9,724,030
6,747,232
224,714
420
231

10,252,856
6,856,590
372,528
445
273

EV-Depleted Plasma (EVD)
T2DM
(Metformin
Treated)
9,146,014
6,254,425
284,460
404
222

Average

Control

T2DM
(Non-Metformin
Treated)

9,707,634
6,619,416
293,901
423
242

10,102,865
7,911,233
535,018
585
323

9,629,667
7,404,532
779,273
642
383

T2DM
(Metformin
Treated)

Average

10,027,784
7,579,322
590,431
624
351

9,920,105
7,631,695
634,907
617
352

Overview of small-RNA sequencing (sRNAseq) results, per group including for each fraction isolated. Raw reads are unfiltered reads, processed reads are after filtering for none-informative
reads, reads mapped to microRNAs (miRNAs) are based on single assignment with no mismatches, Observed miRNA are miRNAs with at least one mapped read.
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(Figure 4C).
(Figure 4C).
In addition to healthy controls, we also compared the miRNA profiles in whole plasma, EVs,
and EV-depleted plasma between T2DM patients with or without metformin treatment. Most of the
affected are from EV-encapsulated miRNA, with 42 miRNAs showed concentration differences with
metformin treatment and only 2 affected miRNAs in whole plasma and none in EV-depleted plasma
(Figure 2I–K). Of the 42 dysregulated miRNAs in EVs, all of them showed decreased concentrations
in T2DM patients treated with metformin compared to their non-treated counterparts, (Figure 2B,J).
Furthermore, many of these miRNAs also showed significant concentration changes between controls
and non-metformin treated T2DM patients (Supplemental Table S2). More of the miRNAs are elevated
in non-metformin treated T2DM patients, whereas metformin-treated T2DM patients have values
comparable to healthy control subjects, specifically in the EV (Figure 5A), but not in the corresponding
EV depleted plasma (Figure 5B).
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In addition to healthy controls, we also compared the miRNA profiles in whole plasma, EVs,
and EV-depleted plasma between T2DM patients with or without metformin treatment. Most of the
affected are from EV-encapsulated miRNA, with 42 miRNAs showed concentration differences with
metformin treatment and only 2 affected miRNAs in whole plasma and none in EV-depleted plasma
(Figure 2I–K). Of the 42 dysregulated miRNAs in EVs, all of them showed decreased concentrations
in T2DM patients treated with metformin compared to their non-treated counterparts, (Figure 2B,J).
Furthermore, many of these miRNAs also showed significant concentration changes between
controls and non-metformin treated T2DM patients (Supplemental Table 2). More of the miRNAs are
elevated in non-metformin treated T2DM patients, whereas metformin-treated T2DM patients have
values comparable to healthy control subjects, specifically in the EV (Figure 5A), but not in the
corresponding EV depleted plasma (Figure 5B).
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million), with each dot representing a patient sample. Statistically significant results are designated by
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4. Discussion
4. Discussion
Circulating miRNAs may show promise as diagnostic and prognostic biomarkers for various
Circulating miRNAs may show promise as diagnostic and prognostic biomarkers for various
diseases and pathologies including T2DM; however, additional studies are needed to identify and
diseases and pathologies including T2DM; however, additional studies are needed to identify and
validate candidate miRNAs of clinical relevance. To understand the impact of T2DM and metformin
validate candidate miRNAs of clinical relevance. To understand the impact of T2DM and metformin
treatment on circulating miRNA, we characterized the miRNAs in whole plasma, EVs, and EVtreatment on circulating miRNA, we characterized the miRNAs in whole plasma, EVs, and EV-depleted
depleted plasma, all from subjects in the fasting state. The EV-depleted plasma contains RNA
plasma, all from subjects in the fasting state. The EV-depleted plasma contains RNA associated with
associated with RNA binding proteins such as AGO2, NPM1[29,30] and lipoproteins—HDL and LDL
RNA binding proteins such as AGO2, NPM1 [29,30] and lipoproteins—HDL and LDL complexes [25].
complexes [25]. Since vesicle encapsulated and protein complexed RNAs arise from very different
Since vesicle encapsulated and protein complexed RNAs arise from very different processes and may
processes and may have different biological implications, analyzing the small RNA content in both
have different biological implications, analyzing the small RNA content in both EV and EV-depleted
EV and EV-depleted plasma gives us a richer view, in principle, of the biological status of the subjects.
plasma gives us a richer view, in principle, of the biological status of the subjects.
In this study we identified 162 circulating miRNAs affected by T2DM in whole plasma, plasma
In this study we identified 162 circulating miRNAs affected by T2DM in whole plasma, plasma
EVs, and EV-depleted plasma. The majority of the affected miRNAs are present in whole plasma as
EVs, and EV-depleted plasma. The majority of the affected miRNAs are present in whole plasma as
well as EV-depleted plasma, while many T2DM-affected miRNAs in EVs were unique, suggesting
well as EV-depleted plasma, while many T2DM-affected miRNAs in EVs were unique, suggesting
EV miRNA are processed by a different mechanism than EV-depleted plasma. This observation
EV miRNA are processed by a different mechanism than EV-depleted plasma. This observation
emphasizes the usefulness of separating EV and EV-depleted biofluid in circulating RNA studies.
emphasizes the usefulness of separating EV and EV-depleted biofluid in circulating RNA studies.
Using qRT-PCR the concentrations changes of several of these T2DM affected miRNAs were verified.
Using qRT-PCR the concentrations changes of several of these T2DM affected miRNAs were verified.
The consistency between qRT-PCR and sRNAseq results suggests that the improved EV isolation,
The consistency between qRT-PCR and sRNAseq results suggests that the improved EV isolation, small
small RNA sequencing library construction method and RNA mapping strategy provide more
RNA sequencing library construction method and RNA mapping strategy provide more accurate small
accurate small RNA profiles.
RNA profiles.
Many of the T2DM affected miRNAs we identified (e.g., miR-122-5p, miR-192-5p, miR-193b-5p,
Many of the T2DM affected miRNAs we identified (e.g., miR-122-5p, miR-192-5p, miR-193b-5p,
miR-146a-5p in plasma/EV depleted plasma; and miR-26a-5p, miR-126-5p, and miR-144-3p in EVs)
miR-146a-5p in plasma/EV depleted plasma; and miR-26a-5p, miR-126-5p, and miR-144-3p in EVs) have
have previously been shown to be dysregulated in T2DM patient plasma/serum samples
(Supplementary Figure S2)[9,13,16,31]; however, this study also identified a number of new T2DM
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previously been shown to be dysregulated in T2DM patient plasma/serum samples (Supplementary
Figure S2) [9,13,16,31]; however, this study also identified a number of new T2DM affected miRNAs,
including, several T2DM affected miRNAs that were observed previously only in animal models or
tissue culture (miR-136-3p, miR-382-5p, miR-495-3p in plasma [16,32] and miR-203a-3p, miR-424-5p in
EVs) [33,34]. We also observed that several of these miRNAs that have been previously observed to be
associated with prediabetes and T2DM (miR-122-5p, miR-192-5p, miR-193b-5p [9,13,15]) show similar
concertation differences between our METSIM and MetaHIT samples sets. The higher concentration
differences of these miRNAs in the MetaHIT cohort likely associated with the difference in dysregulated
metabolic processes between prediabetes and T2DM. It is interesting that after been treated with
metformin the levels of these miRNAs return to similar levels seen in the prediabetic individuals in the
METSIM cohort (Figure 7A–F).
Due to the complex heterogenous nature of plasma and other biofluids, the exact cellular/tissue
sources of these circulating miRNAs (both vesicles and non-vesicle encapsulated) are somewhat
speculative. However, there are some evidences that some of these miRNAs are enriched in tissues
that are associated with T2DM. For example, miR-122-5p has been shown to be expressed highly in the
liver [35], and miR-126-5p, miR-146a-5p, and miR-375-3p have been shown to have some enrichment
in cells of the pancreas [7]. This suggests that some of the dysregulated circulating miRNAs in T2DM
may be derived from these tissues, however additional experiments are required to validate this.
In addition to the effect of T2DM, the impact of metformin treatment on the spectra of circulating
miRNA was also examined. While there was no significant difference in FPG/HbA1c levels between
T2DM patients in this study with or without metformin treatment, the metformin-treated T2DM
patients had significantly higher circulating insulin and C-peptide levels than both non-treated T2DM
patients and healthy controls (Supplementary Table S1) suggesting that these T2DM patients had
a more severe form of insulin resistant T2DM. In addition, we observed that patients treated with
metformin have a spectrum of circulating miRNA more similar to healthy controls in both plasma and
EVs. This suggests that the metformin treatment has a “beneficial” effect based on the restoration of the
circulating miRNA spectrum, though the mechanism for this effect is entirely unclear. When compared
to miRNA levels in non-treated T2DM patients, the levels of some EV-encapsulated miRNAs were
decreased in metformin-treated patients, suggesting a reduction in some miRNA cargo in response
to metformin. For example, the concentrations of several miRNAs including let-7b-5p, miR-15a-5p,
miR-15b-5p, miR-16-5p, miR-16-2-3p, miR-25-3p, miR-30b-5p, miR-106b-3p, miR-195-5p, miR-3613-5p,
and miR-424-5p were increased in T2DM but decreased to the normal range after metformin treatment
(Figure 5A). Unlike the miRNAs discussed above, there is little current evidence of these circulating
miRNAs being involved in T2DM, aside from miR-15a-5p which has been associated with prediabetic
progression to T2DM [31].
Based on the validated gene targets of T2DM affected miRNAs in whole plasma, EVs, and
EV-depleted plasma, we observed enrichment of biological pathways that are potentially associated
with T2DM pathophysiology, including those related to glucose homeostasis, insulin secretion, and
the TGFβ/BMP and Notch signaling pathways (Figure 8). While these pathways are predicted to be
enriched (compared to controls) in non-metformin treated T2DM patients, they are not associated with
patients treated with metformin. While intriguing, further studies are clearly needed to determine if
these changes of biological pathways potentials relate to metformin-treatment associated changes of
biochemical and physiological variables.
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